NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CNS治療藥的全球市場

CNS Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 997779
出版日期 內容資訊 英文 978 Pages
商品交期: 最快1-2個工作天內
價格
CNS治療藥的全球市場 CNS Therapeutics
出版日期: 2021年05月01日內容資訊: 英文 978 Pages
簡介

到2025年,由於對神經疾病的醫療需求未得到滿足,CNS治療的全球市場預計將達到1377億美元。

美國和歐洲是世界上最大的市場,合計佔有70%的佔有率。此外,在分析期間,中國的複合年增長率為7.3%,這得益於以下因素:由於社會結構的變化而導致患精神病的風險增加,消除了與神經系統疾病有關的偏見以及建立了醫療保障體系根據政府政策,預計它將是增長最快的市場。

本報告提供全球CNS治療藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • AbbVie Inc.
  • Alkermes Plc.
  • Allergan Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Eli Lilly and Co.
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi
  • Shire Plc
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Group

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:181公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1835

Abstract:

Global CNS Therapeutics Market to Reach US$144.2 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for CNS Therapeutics estimated at US$103.4 Billion in the year 2020, is projected to reach a revised size of US$144.2 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027.Pain Management, one of the segments analyzed in the report, is projected to grow at a 5.5% CAGR to reach US$41.4 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-Psychotics segment is readjusted to a revised 3.9% CAGR for the next 7-year period. This segment currently accounts for a 14.8% share of the global CNS Therapeutics market.

The U.S. Accounts for Over 27% of Global Market Size in 2020, While China is Forecast to Grow at a 8% CAGR for the Period of 2020-2027

The CNS Therapeutics market in the U.S. is estimated at US$27.9 Billion in the year 2020. The country currently accounts for a 26.98% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$30.6 Billion in the year 2027 trailing a CAGR of 8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR while Rest of European market (as defined in the study) will reach US$30.6 Billion by the year 2027.

Anti-Depressants Segment Corners a 11.8% Share in 2020

In the global Anti-Depressants segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$9.2 Billion in the year 2020 will reach a projected size of US$11.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.4 Billion by the year 2027, while Latin America will expand at a 3.9% CAGR through the analysis period.

Select Competitors (Total 181 Featured) -

  • AbbVie Inc.
  • Alkermes Plc.
  • Allergan Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Eli Lilly and Co.
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi
  • Shire Plc
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Group

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Central Nervous System (CNS) Therapeutics: A Prelude
    • CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
    • List of FDA Approved CNS Drugs: 2019
    • List of FDA Approved CNS Drugs: 2018
    • Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
    • Patent Expiries of Leading CNS Drugs: 2008-2022
    • Developed Markets to Maintain their Dominance
    • Developing Market to Drive the Market Momentum
  • MARKET ANALYSIS BY THERAPEUTIC CATEGORY
    • Anti-Epilepsy Market
    • Global Market Overview
    • Regional Landscape
    • Developed Countries Account for a Major Share of Epilepsy Treatment
    • Developing Countries Struggle with Low Treatment Rates
    • New Approvals (2019 and 2018)
    • Disease Overview
    • EXHIBIT 1: Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
    • EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
    • High Unmet Needs Offer Scope for Market Growth
    • Treatment
    • Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
    • Leading Anti-Epileptic Drugs
    • Leading Anti-Epileptic Drugs and Their Mechanism of Action
    • Patent Expiries of Major Anti-Epilepsy Drugs
    • FDA's New Policy for AED Drugs to Bolster Market Growth
    • AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
    • Select Currently Available Epilepsy Drugs
    • Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
    • Innovative Drugs Needed for Better Treatment Compliance
    • Abounding Potential for NCEs
    • A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
    • FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
    • Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
    • Recent Approvals for Childhood Epilepsy: 2016-2019
    • Review of Anti-Epilepsy Drugs
    • Vimpat®
    • Keppra®
    • Lamictal
    • Tegretol®
    • Sabril®
    • Perampanel
    • Zonegran®
    • Topamax®
    • Trileptal®
    • Neurontin®
    • Lyrica®
    • Depakine®
    • CNS Pain Management
    • Market Overview
    • Treatment
    • Drugs Indicated for Pain Management
    • Select Phase III Ongoing Studies for Cancer Pain
    • Regional Overview
    • Players
    • Combination Therapies Gain Prominence
    • Key Trends in Chronic Pain Management
    • Neuropathic Pain Management: Market with High Potential
    • Select Phase III Ongoing Studies for Neuropathic Pain
    • Lyrica's Generics Gain FDA Approval
    • Migraine Market: A Core Vertical in CNS Pain Management
    • Migraine Care: Select Patent Expiries (2013-2015)
    • Migraine Completed Phase III Studies: As of October 2019
    • Migraine Ongoing Phase III Studies: As of October 2019
    • Select Pain Management Drugs
    • Flupirtine
    • Lyrica
    • Oxycodone
    • Nucynta ER
    • Metabotropic Glutamate Receptors (mGluRs)
    • New Pain Management Drugs
    • Novartis Presents New Data for Aimovig
    • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
    • Three New Migraine Drugs Obtain FDA Approval
    • Eli Lilly's Emgality Receives FDA Approval
    • Anti-Alzheimer's
    • Market Overview
    • EXHIBIT 3: Global Alzheimer's Prevalence by Age Group
    • Alzheimer's Phase III Completed Studies
    • Alzheimer's Phase III Ongoing Studies
    • Treatment for Alzheimer's
    • Select Leading Drugs for Alzheimer's Disease by Drug Category
    • Patent Expiries of Leading Alzheimer's Drugs
    • Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
    • The Clinical Trials for Aducanumab
    • Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer's Market
    • Alzheimer's Drugs: A Market Plagued with Failures
    • Promising Compounds with Silver Lining
    • PRI-002 Gains Success in First Stage of Human Testing for Alzheimer's Disease
    • Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
    • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
    • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
    • Elenbecestat's Phase 3 Trials Halted
    • Novel Drug Delivery Method to the Brain Discovered
    • Alzheimer's Association Provides Grant to Longeveron
    • A Review of Select Anti-Alzheimer's Drugs
    • Aricept
    • Exelon
    • Reminyl
    • Ebixa
    • Namenda
    • A Review of the Alzheimer's disease
    • Alzheimer's Effect on Brain
    • Causes for Alzheimer's
    • Who Are at Risk?
    • Prevalence of Alzheimer's Disease
    • Diagnosis of Alzheimer's
    • Anti-Parkinson's
    • Market Overview
    • EXHIBIT 4: Select Top Selling Drugs for Parkinson's Disease
    • Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
    • Recent Approvals
    • Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
    • Xadago - Add-On Therapy for Parkinson's Disease
    • NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
    • Parkinson's Phase III Completed Studies: As of October 2019
    • Parkinson's Ongoing Phase III Studies: As of October 2019
    • Select Anti-Parkinson's Drugs
    • Levodopa
    • Dopamine Agonists
    • Mirapex
    • FDA Announces Imminent Discontinuation of Certain Formulations of GSK's Requip for PD and RSL Treatment
    • A Review of the Parkinson's Disease
    • Prevalence
    • Symptoms
    • Causes
    • Diagnosis
    • Anti-Depressants
    • Market Overview
    • EXHIBIT 5: Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
    • Anti-Depressant Treatment
    • EXHIBIT 6: Select Top Selling Anti-Depressants in 2018
    • Select Antidepressants Drugs
    • Zoloft (Sertraline)
    • Cymbalta®
    • Prozac (Fluoxetine)
    • Effexor (Venlafaxine)
    • Paxil
    • Wellbutrin (Bupropion)
    • Recent Approvals of Anti-Depressants
    • Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
    • Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
    • A Review of Depression
    • Prevalence of Depression
    • Causes of Depression
    • Types of Depressive Disorders
    • Available Treatment
    • Tricyclic Antidepressants
    • Monoamine Oxidase Inhibitors
    • Lithium Salts
    • Working of Antidepressants
    • Ranking of Antidepressants in Terms of Efficacy
    • Types of Antidepressants
    • NMDA Receptor Antagonists
    • NMDA Receptor (NMDAR)
    • NMDA Receptor Agonists
    • Acetylcholinesterase Inhibitors
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Workings of SSRIs
    • Safety Levels of SSRI Drugs
    • Adverse Effects of SSRI
    • Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
    • Anti-Psychotics
    • Market Overview
    • Leading Atypical Antipsychotics for the Treatment of Schizophrenia
    • Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
    • Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
    • Select Anti-Psychotic Drugs
    • Zyprexa
    • Seroquel
    • Abilify
    • Clozaril
    • Risperdal
    • Risperdal® Consta®
    • Geodon
    • Invega Sustenna
    • Saphris
    • Latuda
    • A Review of Anti-Psychotics
    • Indications of Antipsychotics
    • An Effective Adjunctive Therapy
    • Off-label Uses
    • Efficacy - Marred by Lack of Evidence Base
    • Types of Antipsychotics
    • Difference between Typical and Atypical
    • Atypical Antipsychotics Up Against Typicals
    • Side Effects of Antipsychotics
    • Symptoms of Antipsychotics Withdrawal
    • Bipolar Disorder
    • Symptoms of Bipolar Disorder
    • Mood Episode - A Major Symptom
    • Manic Episode Vs Depressive Episode
    • Causes of Bipolar Disorder
    • Types of Bipolar Disorder
    • Co-morbidities of Bipolar Disorder
    • Schizophrenia
    • Prevalence by Gender
    • Symptoms of Schizophrenia
    • Causes of Schizophrenia
    • Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
    • Multiple Sclerosis (MS)
    • List of Approved Drugs for MS
    • Patent Expiration Date/Year of the Major MS Drugs
    • EXHIBIT 7: Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
    • New Approvals
    • Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
    • Mavenclad Gains FDA Approval
    • Celgene Files NDA for Ozanimod
    • Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
    • Multiple Sclerosis: Pipeline Analysis
    • Pipeline Drugs in Phase III for Multiple Sclerosis: As of October 2019
    • A Review of Multiple Sclerosis (MS)
    • Types of Multiple Sclerosis
    • EXHIBIT 8: Clinical Subtypes of Multiple Sclerosis (MS)
    • Prevalence of MS
    • Causes of MS
    • Myths Surrounding Multiple Sclerosis
    • Symptoms of MS
    • Diagnosis of MS
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Market Overview
    • Approved Drugs for ADHD: 2017
    • Sales of Vyvanse in 2018
    • Pipeline Drugs in Phase III for ADHD: As of October 2019
    • Select ADHD Drugs
    • Vyvanse
    • Concerta
    • Adderall
    • A Review of Attention Deficit Hyperactivity Disorder (ADHD)
    • Consequences of ADHD
    • What Leads to ADHD?
    • Insomnia
    • Overview
    • List of Approved Drugs for Insomnia
    • Pipeline Drugs for Insomnia: As of October 2019
    • Zolpidem
    • Eszopiclone
    • A Review of Insomnia
    • Prevalence of Insomnia
    • Therapies for Insomnia
  • 2. FOCUS ON SELECT PLAYERS
    • AbbVie Inc. (USA)
    • Alkermes Plc. (Ireland)
    • Allergan Plc. (Ireland)
    • AstraZeneca Plc. (UK)
    • BIAL Group (Portugal)
    • Bristol-Myers Squibb (USA)
    • Eisai Co., Ltd. (Japan)
    • Endo Pharmaceuticals Inc. (USA)
    • Eli Lilly and Co. (USA)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Fabre-Kramer Pharmaceuticals, Inc. (USA)
    • GlaxoSmithKline (UK)
    • H. Lundbeck A/S (Denmark)
    • Johnson & Johnson (USA)
    • Janssen Pharmaceuticals, Inc. (USA)
    • Merck & Co., Inc. (USA)
    • Neurocrine Biosciences, Inc. (USA)
    • Novartis AG (Switzerland)
    • Otsuka Pharmaceutical Co., Ltd. (Japan)
    • Pfizer, Inc. (USA)
    • Purdue Pharma L.P. (USA)
    • Sanofi (France)
    • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
    • Sunovion Pharmaceuticals, Inc. (USA)
    • Takeda Pharmaceutical Co., Ltd. (Japan)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • UCB S.A., (Belgium)
  • 3. MARKET TRENDS & DRIVERS
    • Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
    • EXHIBIT 9: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
    • Rising Healthcare Expenditure to Boost CNS Therapeutics Market
    • EXHIBIT 10: World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
    • EXHIBIT 11: Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
    • Growing Middle Class Population in Emerging Regions to Spur the Market
    • EXHIBIT 12: Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
    • EXHIBIT 13: Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
    • Growing Penetration of Generic Drugs Emerges as a Key Trait
    • EXHIBIT 14: Global Spending on Generic Drugs Vis-a-vis Branded Drugs (2019): Percentage Share Breakdown of Dollar Spending by Drug Category
    • Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
    • Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
    • Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
    • Awareness Campaigns Launched by Pharma Companies to Benefit the Market…
    • Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
    • New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Anti-Depressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Anti-Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Anti-Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Anti-Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Anti-Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Anti-Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Anti-Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Anti-Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Anti-Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Anti-Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Aging Population: A Strong Demographic Driver
    • EXHIBIT 15: North American Elderly Population by Age Group (1975-2050)
    • The Largest CNS Therapeutics Market Globally
    • Patent Expiries of Leading CNS Drugs in the US
    • Focus on Select Markets
    • Alzheimer's Market
    • Anti-depressant Drugs
    • Usage of Antidepressants Surges in the US
    • Anti-Epilepsy Market
    • Epilepsy - A Major Concern for the Healthcare Industry
    • A Glance at Epilepsy Statistics
    • Anti-Epilepsy Drugs
    • The US Epilepsy Market: Patent Expiry of Select Major Drugs
    • Epilepsy in Children
    • Growing Competition from Generics
    • Pain Management Market
    • Consumers in the US Seek Different Options for Chronic Pain Management
    • Neuropathic Pain Market
    • Anti-Psychotic Drugs Market
    • Mental Illnesses - Epidemiology
    • Facts & Figures
    • EXHIBIT 16: Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
    • Popular Antipsychotic Drugs in the US
    • TABLE 40: The US Anti-Psychotic Drugs Market by Indication (2019E): Percentage Share Breakdown of Value Sales
    • Surging Off-label Prescriptions
    • Generics Occupy Front Seat
    • Rising Antipsychotic Use among Children - A Cause of Concern
    • ADHD Market
    • Select Available ADHD Drugs in the US
    • EXHIBIT 17: The US ADHD Drugs Market by Drug Category (2019E): Market Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants
    • EXHIBIT 18: The US ADHD Drugs Market by Type (2019E): Market Share Breakdown of Total Prescription Sales for Branded & Generic Drugs Groups
    • Adult ADHD Drugs Continue to Widen their Share
    • EXHIBIT 19: The US ADHD Drugs Market by Drug Category (2019E): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups
    • Market Analytics
    • TABLE 25: USA Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • CANADA
    • CNS Diseases: Facts & Figures
    • TABLE 28: Canada Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • CHINA
    • China: The Primary Market for CNS Drugs in Asia-Pacific
    • Select Anti-Schizophrenia Drugs Available in China
    • Other Available CNS Drugs in China
    • TABLE 34: China Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • EUROPE
    • European Patent Expiries of Select CNS Drugs
    • Pain Management Market
    • Neuropathic Pain Market Witnesses Foray of Generics
    • Anti-Psychotics Market
    • Demand for Antipsychotics for Bipolar Disorder Upbeat
    • Ageing Population Boosts Demand
    • EXHIBIT 20: 65+ Population as Percentage of Total Population for Major Countries in Europe: As on June 2019
    • TABLE 37: Europe Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 40: Europe Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 43: France Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: France Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: France 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 46: Germany Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Germany Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Germany 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ITALY
    • Market Snapshots
    • TABLE 49: Italy Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Italy Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Italy 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • NICE Recommendations on CNS Therapeutics
    • TABLE 52: UK Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: UK Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: UK 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 55: Spain Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Spain Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Spain 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 58: Russia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Russia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Russia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 61: Rest of Europe Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Rest of Europe Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Rest of Europe 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • India & China Offer Significant Growth Opportunities
    • Growing Antipsychotics Market in Asia
    • TABLE 64: Asia-Pacific Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 65: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Asia-Pacific 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 67: Asia-Pacific Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Asia-Pacific Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Asia-Pacific 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 70: Australia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Australia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Australia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 73: India Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: India Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: India 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 76: South Korea Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: South Korea Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: South Korea 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 79: Rest of Asia-Pacific Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Rest of Asia-Pacific 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 82: Latin America Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 83: Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Latin America 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 85: Latin America Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Latin America Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Latin America 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 88: Argentina Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Argentina Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Argentina 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 91: Brazil Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Brazil Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Brazil 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 94: Mexico Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Mexico Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Mexico 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 97: Rest of Latin America Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Latin America Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of Latin America 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 100: Middle East Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 101: Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Middle East 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 103: Middle East Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Middle East Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Middle East 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 106: Iran Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Iran Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Iran 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 109: Israel Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Israel Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Israel 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 112: Saudi Arabia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Saudi Arabia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Saudi Arabia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 115: UAE Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UAE Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: UAE 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 118: Rest of Middle East Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Middle East Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Middle East 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 121: Africa Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Africa Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Africa 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 181